Leveraging real-world evidence to bridge the access gap in multiple myeloma

*Partnered Content

An Expert View from Tomislav Kamenski, Senior Director, Therapy Area Market Access Leader, Hematology, Johnson & Johnson (NYSE: JNJ).

In the field of oncology, we are currently witnessing the most rapid period of innovation in medical history.1 The approval of new cancer therapies, alongside advancements in diagnostics, surgery, and overall healthcare, are offering optimism to individuals facing cancers traditionally associated with poor outcomes, low survival rates, and treatment challenges.1 Take, for instance, the remarkable progress in multiple myeloma. Over the past two decades, survival rates have drastically improved – in some cases, doubling.2 I am optimistic that these encouraging statistics are set to continue improving with the introduction of increasingly targeted immunotherapy agents, such as bispecific antibodies and CAR-T cell therapies, as well as a focus on diagnosing and treating multiple myeloma earlier.3